BTR Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $8.2M | Buy |
103,358
+4,280
| +4% | +$361K | 1.28% | 30 |
|
|
2022
Q2 | $7.36M | Buy |
99,078
+954
| +1% | +$71.6K | 1.06% | 31 |
|
|
2022
Q1 | $8.82M | Sell |
98,124
-358
| -0.4% | -$33.1K | 1.08% | 30 |
|
|
2021
Q4 | $11M | Buy |
98,482
+1,313
| +1% | +$158K | 1.24% | 30 |
|
|
2021
Q3 | $12.2M | Buy |
97,169
+2,053
| +2% | +$264K | 1.51% | 28 |
|
|
2021
Q2 | $12.9M | Buy |
95,116
+940
| +1% | +$124K | 1.61% | 26 |
|
|
2021
Q1 | $12.8M | Buy |
94,176
+3,839
| +4% | +$575K | 1.86% | 22 |
|
|
2020
Q4 | $12.7M | Sell |
90,337
-1,477
| -2% | -$189K | 1.99% | 18 |
|
|
2020
Q3 | $10.2M | Sell |
91,814
-1,973
| -2% | -$221K | 1.81% | 20 |
|
|
2020
Q2 | $10.5M | Sell |
93,787
-22,084
| -19% | -$2.17M | 1.97% | 20 |
|
|
2020
Q1 | $8.97M | Buy |
115,871
+17,674
| +18% | +$1.57M | 1.99% | 19 |
|
|
2019
Q4 | $9.34M | Buy |
98,197
+520
| +0.5% | +$45K | 1.61% | 23 |
|
|
2019
Q3 | $7.45M | Buy |
97,677
+381
| +0.4% | +$31.7K | 1.4% | 26 |
|
|
2019
Q2 | $8.53M | Sell |
97,296
-825
| -0.8% | -$70.4K | 1.59% | 21 |
|
|
2019
Q1 | $8.88M | Sell |
98,121
-1,480
| -1% | -$126K | 1.71% | 20 |
|
|
2018
Q4 | $7.15M | Sell |
99,601
-3,515
| -3% | -$283K | 1.5% | 24 |
|
|
2018
Q3 | $9.89M | Sell |
103,116
-140
| -0.1% | -$13.6K | 1.72% | 22 |
|
|
2018
Q2 | $9.83M | Buy |
103,256
+495
| +0.5% | +$45.5K | 1.89% | 19 |
|
|
2018
Q1 | $9.02M | Sell |
102,761
-2,387
| -2% | -$218K | 1.8% | 22 |
|
|
2017
Q4 | $8.92M | Sell |
105,148
-240
| -0.2% | -$20.1K | 1.75% | 23 |
|
|
2017
Q3 | $9.12M | Sell |
105,388
-60
| -0.1% | -$4.81K | 1.86% | 20 |
|
|
2017
Q2 | $8.14M | Sell |
105,448
-495
| -0.5% | -$35.1K | 1.67% | 25 |
|
|
2017
Q1 | $7.35M | Buy |
105,943
+2,875
| +3% | +$193K | 1.54% | 29 |
|
|
2016
Q4 | $6.83M | Hold |
103,068
| – | – | 1.53% | 29 |
|
|
2016
Q3 | $6.83M | Buy |
103,068
+91,185
| +767% | +$5.64M | 1.53% | 29 |
|
|
2016
Q2 | $643K | Buy |
11,883
+420
| +4% | +$23K | 0.15% | 99 |
|
|
2016
Q1 | $592K | Sell |
11,463
-900
| -7% | -$46.7K | 0.14% | 104 |
|
|
2015
Q4 | $868K | Hold |
12,363
| – | – | 0.2% | 87 |
|
|
2015
Q3 | $770K | Sell |
12,363
-26,898
| -69% | -$2.12M | 0.18% | 94 |
|
|
2015
Q2 | $3.3M | Sell |
39,261
-8,979
| -19% | -$698K | 0.78% | 45 |
|
|
2015
Q1 | $3.63M | Sell |
48,240
-25,710
| -35% | -$1.8M | 0.88% | 43 |
|
|
2014
Q4 | $4.6M | Sell |
73,950
-4,005
| -5% | -$228K | 1.25% | 33 |
|
|
2014
Q3 | $4.05M | Buy |
77,955
+735
| +1% | +$37.5K | 1.12% | 37 |
|
|
2014
Q2 | $3.96M | Sell |
77,220
-795
| -1% | -$35.8K | 1.09% | 38 |
|
|
2014
Q1 | $3.71M | Buy |
78,015
+81
| +0.1% | +$4.15K | 1.08% | 36 |
|
|
2013
Q4 | $3.38M | Buy |
77,934
+11,235
| +17% | +$465K | 0.96% | 42 |
|
|
2013
Q3 | $2.87M | Sell |
66,699
-3,840
| -5% | -$156K | 0.9% | 42 |
|
|
2013
Q2 | $2.45M | Buy |
+70,539
| New | +$2.48M | 0.76% | 45 |
|
Other funds holding XBI
CI
APM
BTR Capital Management's XBI Position: Q3 2022 in Review
BTR Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 4.3% in Q3 2022, buying an estimated $361K and bringing the position to 103,358 shares worth $8.2M. The position accounts for 1.28% of the portfolio, ranked #30.
BTR Capital Management first reported a position in XBI in Q2 2013 and has held it in 38 quarters since. The position peaked at $12.9M in Q2 2021. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.
- BTR Capital Management held 103,358 shares of State Street SPDR S&P Biotech ETF worth $8.2M as of Q3 2022.
- BTR Capital Management bought 4,280 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $361K.
- State Street SPDR S&P Biotech ETF made up 1.28% of BTR Capital Management's portfolio in Q3 2022, its #30 holding.
- BTR Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 38 quarters since.
- BTR Capital Management's State Street SPDR S&P Biotech ETF position peaked at $12.9M in Q2 2021.
- 704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.
Based on BTR Capital Management's 13F filing for Q3 2022, filed 12 Oct 2022.